Immunovant posts a wider Q2 loss as R&D spending rises, but progress on IMVT-1402 and batoclimab fuels its pipeline momentum.

Immunovant posts a wider Q2 loss as R&D spending rises, but progress on IMVT-1402 and batoclimab fuels its pipeline momentum.

CRISPR Therapeutics posts a narrower-than-expected Q3 loss, trims R&D spend, and advances late-stage and next-gen gene-editing programs.

KRO posts a wider-than-expected Q3 loss as lower TiO2 prices and weak demand hit sales, with volumes under pressure.

EDIT reports narrower Q3 loss, boosts revenues on a Bristol Myers milestone, and advances in vivo gene-editing program with EDIT-401.

EDIT reports narrower Q3 loss, boosts revenues on a Bristol Myers milestone, and advances in vivo gene-editing program with EDIT-401.

PBF posts narrower Q3 loss as cost cuts lift results, though revenues and throughput volumes fall year over year.

PBF posts narrower Q3 loss as cost cuts lift results, though revenues and throughput volumes fall year over year.

WULF's Q3 revenues surge 87% to $50.6 million with first HPC revenues of $7.2 million, but EPS misses estimates.

WULF's Q3 revenues surge 87% to $50.6 million with first HPC revenues of $7.2 million, but EPS misses estimates.